Key Drivers
- Strong Cash Position
- Earnings Quality Risk
- Meaningful Dilution
AIAI Summary
PTGX has shifted into a cash-rich, royalty-platform story, but at a premium valuation investors should demand sustained MIMRYLO and ICOTYDE royalty growth—not milestone-driven earnings—before adding exposure.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Cash Position
- •Earnings Quality Risk
- •Meaningful Dilution
PTGX posted exceptional quarterly profitability and liquidity gains, but investors should scrutinize earnings durability, dilution, and its demanding valuation.
Price Behavior
Key Price Behavior Insights:
- •Lower-price sequence
- •Support test
- •Rebound failures
PTGX remains technically cautious after falling over the last month, with $142.84–$143.00 support needing to hold and a reclaim of $145.70–$148.20 needed to improve momentum.
Decline accelerated after the $154.72 late-August high
Sentiment & News
Key News Insights:
- •FDA approval
- •$300M buyback
- •CEO share sales
Protagonist's FDA approval of MIMRYLO and $300M buyback strengthen its outlook, though sizable CEO share sales temper sentiment.
The regulatory milestone and capital return program are positive catalysts, but insider selling may create near-term caution
Similar Companies in Healthcare
Other companies in the same sector with AI ratings